Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

universities

- PMLiVE

Sanofi shares positive phase 3 results for Sarclisa in newly diagnosed multiple myeloma

More than 180,000 new cases of the haematological malignancy are diagnosed globally every year

- PMLiVE

Innovative Trials partners with GOSH and Oliver Patch for childhood cancer research

Childhood cancers, including leukaemia and lymphoma, affect 400,000 children globally every year

- PMLiVE

UCLA launches study of personalised cancer vaccine in paediatric brain tumours

H3 G34-mutant diffuse hemispheric gliomas are brain tumours commonly found in adolescents and young adults

- PMLiVE

Eisai and SEED enter molecular glue degrader partnership worth up to $1.5bn

The companies are aiming to develop candidates for multiple neurodegeneration and oncology targets

- PMLiVE

Researchers develop immunotherapy to prevent prostate cancer treatment resistance

The second-most common cancer in the UK affects more than 52,000 men every year

- PMLiVE

ALX Oncology’s evorpacept shows promise as gastric cancer combination treatment

More than 6,500 new diagnoses of gastric cancer are made in the UK every year

- PMLiVE

Innovative Trials Announces New Charity Partnerships

Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year

Innovative Trials

- PMLiVE

AstraZeneca signs exclusive licensing deal worth over $500m for Pinetree’s EGFR degrader

The candidate has shown promising preclinical anti-tumour activity in drug- and TKI-resistant tumours

- PMLiVE

Ipsen gains ex-US rights to Day One’s brain cancer therapy in deal worth over $460m

Paediatric low-grade gliomas are the most common type of brain tumour diagnosed in children

- PMLiVE

Novartis and Dren Bio enter bispecific antibody partnership worth up to $3bn

The companies will aim to advance targeted myeloid engager programmes in oncology

- PMLiVE

ICR study on cell competition mechanism could lead to new ways of treating cancer

Female breast, lung, bowel and prostate cancers account for more than four in ten of all cancers worldwide

- PMLiVE

Researchers develop AI model to identify breast cancer stages and progression

Up to 50% of ductal carcinoma in situ patients progress to a highly invasive stage of cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links